Q-Line Biotech
- Market cap
- ₹ 1,229 Cr.
- P/E
- 22.4x
- P/B
- 6.99x
- 52-week range
- 431 – 735
- ROE
- 26%
- ROCE
- 22%
- Debt / equity
- 0.88
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE SME
About
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) and consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The Company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors, who in turn sell its products to hospitals/diagnostic centers or directly to diagnostic service providers and hospitals. It has developed a diversified product portfolio in the IVD industry which includes reagents, point of care devices and kits used in clinical chemistry, coagulation, hematology, HPLC, rapid/ELISA, molecular, diagnostic instruments, equipment, consumables and services. It markets these products in around 26 states and the Union Territory with specific focus on Utter Pradesh, Rajasthan, Madhya Pradesh, Kerala and Odisha.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Q-Line Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)22.4 against a typical 28.7: cheaper than most peers (1st = cheapest).10th of 25
- Share price, 3 months+6.5% against a typical −7.9%.6th of 23
- Size₹ 1,229.4 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).5th of 24
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Withdrawn | — | 26 Jun 2026 |
Every agency has withdrawn its rating.
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 26 Jun 2026 | Withdrawn | — | — | CRISIL | ₹ 169 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Sep 2026 | Board Meeting Intimation | Q-LINE BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 05-Sep-2026 to consider Other business. |
| 17 Jun 2026 | Financial Results/Other business matters | inter alia, 1. To consider and approve the Standalone & Consolidated Audited Financial Results of the Company for the Financial Year ended 31st March, 2026 along with the Statement of Assets and Liabilities as on that date and Cash Flow Statement for the financial year ended 31st March, 2026 and to take on record Auditor s Report thereon by the Statutory Auditors of the Company.2. To Consider and Approve the Internal Audit Report of the Company.3. Any other business with permission of the Chair, if any. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21% | 31% |
| Other Income | −11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| Profit before tax | 22 | 46 |
| Tax % | 71% | 26% |
| Net Profit | 9 | 34 |
| EPS in Rs | 56.13 | 21.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 23%
- TTM
- 9%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 21%
- TTM
- 25%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 25%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Q-Line Biotech | ₹ 541.00 | ₹ 1,229 Cr. | 22.4x | 7x | 26% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Saurabh Garg
- Chairman of the Board, Managing Director
- Meenal Gupta
- Chief Financial Officer
- Akhand Pratap Singh
- Compliance Officer, Company Secretary
- Kuldeep Chowdhry
- Whole Time Director
- Ajay Kumar Mahanty
- Whole Time Director
- Yethadka Subraya Prabhakara
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.